Financial burden, distress, and toxicity in cardiovascular disease - 19/06/21
Highlights |
• | Cardiovascular disease (CVD) is a major source of financial burden and financial distress, which can cause psychological distress, cost-related care non-adherence or care deferral, and create tradeoffs with basic needs. |
• | To reduce financial distress, policymakers can expand insurance coverage, health systems can limit expenditure on low-benefit, high-cost treatments, physicians can engage in shared-decision-making for high-cost interventions, and community-based initiatives can support patients with system navigation and financial coping. |
• | Avenues for research include analysis of how healthcare policies affect financial burden, comparative effectiveness studies examining high and low-cost strategies for CVD management and testing interventions to reduce financial burden. |
Résumé |
Cardiovascular disease (CVD) is a major source of financial burden and distress, which has 3 main domains: (1) psychological distress; (2) cost-related care non-adherence or medical care deferral, and (3) tradeoffs with basic non-medical needs. We propose 4 ways to reduce financial distress in CVD: (1) policymakers can expand insurance coverage and curtail underinsurance; (2) health systems can limit expenditure on low-benefit, high-cost treatments while developing services for high-risk individuals; (3) physicians can engage in shared-decision-making for high-cost interventions, and (4) community-based initiatives can support patients with system navigation and financial coping. Avenues for research include (1) analysis of how healthcare policies affect financial burden; (2) comparative effectiveness studies examining high and low-cost strategies for CVD management; and (3) studying interventions to reduce financial burden, financial coaching, and community health worker integration.
Le texte complet de cet article est disponible en PDF.Plan
Vol 238
P. 75-84 - août 2021 Retour au numéro
Article précédent
- Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial
- Xiulin Shi, Jiang He, Mingzhu Lin, Changqin Liu, Bing Yan, Haiqu Song, Caihong Wang, Fangsen Xiao, Peiying Huang, Liying Wang, Zhibin Li, Yinxiang Huang, Mulin Zhang, Chung-Shiuan Chen, Katherine Obst, Weihua Li, Shuyu Yang, Guanhua Yao, Xuejun Li
- Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention
- Charan Yerasi, Brian C. Case, Chava Chezar-Azerrad, Brian J. Forrestal, Giorgio A. Medranda, Corey Shea, Cheng Zhang, Itsik Ben-Dor, Lowell F. Satler, Nelson L. Bernardo, Hayder Hashim, Hector M. Garcia-Garcia, Ron Waksman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?